CD30, a member of the tumor necrosis factor receptor (TNFR) superfamily, is consistently expressed by tumor cells of anaplastic large-cell lymphoma (ALCL). CD30 stimulation induces massive caspase-dependent cell death of ALCL cells in case of canonical NFkB inhibition or proteasome inhibition. However, CD30, a TNFR lacking a death domain (DD), is unable to recruit a death inducing complex containing TRADD (TNFR1-associated DD-protein) or FADD (FAS-associated DD-domain protein) together with the receptor-interacting protein 1 (RIP1) and caspase-8. Thus, the mechanism explaining CD30-induced cell death of lymphocytes remains obscure. Here, we demonstrate that blockage of RIP1 by siRNA or pharmacological inhibition of RIP1 by Necrostatin-1 almost completely prevented CD30-induced cell death. In addition, we revealed CD30-induced accumulation of RIP1 at the cytoplasma membrane of NFkB-inhibited ALCL cells by confocal laser scanning microscopy. Finally, primary ALCL cases can be subdivided into two groups based on the presence or absence of RIP1 as revealed by immunohistology. Taken together, our study identified RIP1 as a crucial mediator of CD30-induced cell death that bears features of apoptosis as well as necroptosis. RIP1 expression in ALCL tumor cells might eligible for the therapeutic application of CD30 antibodies in combination with NFkB/proteasome inhibitors that should result in CD30-induced cell death.
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CD30 belongs to the superfamily of tumor necrosis factor receptors (TNFR) and is predominantly expressed by tumor cells (Hodgkin and Reed Sternberg cells (HRS)) of classical
Hodgkin lymphoma (cHL) and those of anaplastic large-cell lymphoma (ALCL). In normal tissue, CD30 expression is restricted to a subset of activated T and B cells. 1 This selective and restricted expression strongly recommends CD30 as a therapeutic target. 2 To this end, the knowledge of CD30-driven effects and their underlying molecular mechanisms are mandatory. Comprehensive molecular analysis revealed that CD30 stimulation of ALCL cells mediates dramatic changes of mRNA and protein expression, resulting in cell cycle arrest without induction of cell death. 3, 4 Interestingly, a different pathway of CD30 signaling, ie, induction of massive cell death, becomes apparent under the condition of nuclear factor kB (NFkB) inhibition by means of stable transfection with a dominant-negative NFkB inhibitor (IkBaDN) 4 or proteasome inhibition. 5 CD30-induced cell death of lymphocytes was further reported to occur under serum reduction, which was attributed to autocrine TNF. 6 Of note, an involvement of autocrine TNF in terms of CD30-induced cell death under NFkB-inhibited condition is not established. Receptor-interacting protein 1 (RIP1) is a death homology domain (DD)-containing serine/threonine kinase. RIP1 participates in the signaling complexes that assemble upon activation of cell surface receptors, such as TLR3, TLR4, TNFR1, TRAILR, CD95/Fas, and CD40. [7] [8] [9] Except TLR3, TLR4, and CD40, the numerated receptors belong to the subgroup of death receptors (DRs) carrying a DD. [10] [11] [12] RIP1 is crucial for all three discriminable cell fates following TNFR1 stimulation: (i) NFkB-promoted survival, (ii) apoptosis, or (iii) programmed necrosis (necroptosis). 13, 14 Necroptosis refers to a regulated form of necrosis, 15 and is biochemically defined as a form of presumably caspase-independent, RIP1-dependent cell death. 16 The kinase activity of RIP1 is specifically important for the regulation of necroptosis and inhibited by Necrostatin-1 (Nec-1). 17 Upon ligand binding, TNFR1 trimers undergo conformational changes that allow the cytoplasmic portions of receptors to recruit multiple proteins, including TNFR-associated death domain (TRADD), cellular inhibitor of apoptosis 1 (cIAP1), cIAP2, TNFR-associated factor 2 (TRAF2), TRAF5, and RIP1. This DD-associated, membrane -proximal structure has been named complex I. 10 TRAF2 stabilizes cIAP1 and cIAP2 by preventing their polyubiquitylation. cIAP1/2 represent E3 ubiquitin ligases of RIP1. 18, 19 The site of ubiquitin addition determines the mode of RIP1 action. K63-linked ubiquitin chains are conjugated by IAPs and convey RIP1 to a scaffold molecule at the TNF receptor complex. Subsequently, transforming growth factor-b-activated kinase 1 (TAK1), TAK1-binding protein 2 (TAB2), and TAB3 are bound to this membrane associated complex (complex 1) that mediates NFkB and MAPK activation, followed by the expression of prosurvival genes. 13, 14 Further, it is well documented that RIP1 represents an integral component of the TNFR-uncoupled cytoplasmic apoptosis-inducing signaling complex. 10, 20 Although, CD30 does not belong to DD-carrying TNFRs, we and others demonstrated that CD30 stimulation induces cell death under NFkB-inhibited condition 4, 5 that is inhibited by the pan-caspase inhibitor z-VAD-fmk. 4 Here, we uncovered the intracellular mechanisms of CD30-mediated cell death and identified RIP1 as the molecular link between CD30 and cell death induction. These findings might be valuable for NFkB-associated CD30-targeted therapies.
MATERIALS AND METHODS

Cell Lines
The cell lines DEL, SUPM2, SU-DHL1, SR 786, Karpas 299 (ALCL), and HeLa (carcinoma of the cervix uteri) were obtained from the German Resource Center for Biological Material (DSMZ, Braunschweig, Germany). The ALCL cell lines JB6, Mac-1, and FEPD were generous gifts from Dr M.E. Kadin (Harvard Medical School, Boston, MA, USA) and Dr K. Pulford (John Radcliff Hospital, University of Oxford, Oxford, UK), respectively. Comparative experiments were performed with the constitutively NFkB-inhibited cell line IkBaDN-Karpas 299 (abbreviated DN-Karpas 299) that was stable transfected with the dominant-negative NFkB inhibitor IkBaDN. 4 Cells were maintained in RPMI 1640 (PAA, Pasching, Austria) supplemented with 10% (v/v) fetal bovine serum (PAA) and 4 mM glutamine at 5% (v/v) CO 2 and 37 1C. 
Flow Cytometry
Staining of dead/apoptotic cells was performed with the Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences Pharmingen, Heidelberg, Germany) according to manufacturers' instructions. Labeled cells were analyzed by a FACSort or Accuri C6 (Becton Dickinson, Heidelberg, Germany). CD30L was stained by goat-antibody (Santa Cruz), detected by anti-goat-biotin and PE-conjugated Streptavidin (DakoCytomation, Hamburg, Germany).
RNA Extraction and Reverse Transcription-Relative Quantitative-Real Time-PCR (RT-RQ-PCR)
Total RNA of RIP1 siRNA-treated/control siRNA-treated and control/CD30-stimulated ALCL cells was extracted, according to standard protocols (Qiagen, Hilden, Germany). RT-RQ-PCR was carried out as published 22 with the following pairs of oligonucleotides (forward/reverse): A20:
HPRT served as endogenous control. HPRT-normalized gene expression was calculated by the 2 À DD CT method. 23 
RIP1 Inhibition Experiments
Downregulation of RIP1 in Karpas 299 and DN-Karpas 299 cells was performed by RIP1 siRNA (ON TARGET plus SMART pool, Thermo Scientific/Dharmacon, Erembodegem, Belgium) transfection (Amaxa, Köln, Germany), consisting of four different RIP1 siRNAs. Mock-transfections were performed by control siRNA (non-targeting pool, Thermo Scientific/ Dharmacon). In addition, RIP1 was inhibited pharmacologically by Nec-1 (Biomol, Hamburg, Germany) or Geldanamycin (GA, Sigma-Aldrich). Subsequently, cells were CD30-stimulated or control-treated for the indicated times. Downregulation of RIP1 was monitored by immunoblot analysis.
Processing of Microarray Data
Gene-expression data were obtained from three publicly available data bases (GSE6338, GSE14879, and GSE19069 at the National Center for Biotechnology Information Gene Expression Omnibus repository http://www.ncbi.nlm. nih.gov/geo/ ). [24] [25] [26] Expression values were extracted from Affymetrix chip definition files and manufacturer's annotations for HG-U133 Plus 2.0 arrays. CEL-files were imported into Partek Genomic Suite Software (Version 6.4; Partek, St Louis, Missouri, USA) and processed by the implemented robust multiarray (RMA) workflow (median polish probe set summarization, RMA background correction and quantile normalization).
Statistical Analysis
Data were statistically analyzed using the Student t-test (unpaired, two-tailed, 95% confidence interval). In addition to canonical NFkB-pathway, we investigated CD30-mediated non-canonical NFkB-pathway activation. As depicted in Figure 1c To elucidate whether autocrine TNF was involved in CD30-induced cell death of DN-Karpas 299 cells, we preincubated cells with a TNF-neutralizing monoclonal antibody (D1B4) at 500 ng/ml for 0.5 h and performed CD30 or TNFR1 stimulation for 16 h, subsequently. D1B4 completely blocked TNF-induced cell death of DN-K299 cells (Figure 1a,  panel 7) . In contrast, CD30-induced cell death was not affected by TNF-neutralization ( Figure 1a, panel 8) . These findings clearly indicated that autocrine TNF was not involved in CD30-induced cell death of DN-Karpas 299 cells.
RESULTS
CD30 Stimulation Induced Cell Death in NFjB Pathway
CD30-Induced Cell Death was Mediated by RIP1 in DN-Karpas 299 Cells
The consistent expression of RIP1 protein of all untreated ALCL cell lines and HeLa cells that have been investigated in this study is shown in Figure 1g by immunoblot. As RIP1 represents an important component of DD-carrying TNFRsignaling complexes, we reasoned whether it also participates 
Low cIAP2 Expression was not Responsible for CD30-or TNF-Induced Cell Death in DN-Karpas 299 Cells
Previously, we and others demonstrated that cIAP2 expression was significantly induced by CD30 stimulation of different ALCL cell lines, including Karpas 299. 4, 27 Here, we showed that CD30 stimulation of DN-Karpas 299 cells did not increase cIAP2 expression (Figure 2b) . Based on the fact that cIAP2 represents an ubiquitin ligase, mediating K63-linked RIP1 ubiquitination, 19 we wondered whether consistently low cIAP2 expression as revealed in DN-Karpas 299 cells might be involved in the CD30-and TNF-mediated cell death. To address this issue, we pre-incubated Karpas 299 cells with 1 mM Smac mimetic (BV6; IAP inhibitor) for 2 h and performed a CD30 or TNF stimulation for 16 h, subsequently. BV6 almost completely abolished cIAP2 expression and to a lesser extent cIAP1 expression as demonstrated by immunoblot (Figure 2e ) and abrogated CD30-and TNF-mediated upregulation of cIAP2 as 
RIP1 Expression of Primary Cases of Systemic ALCL
We also investigated RIP1 expression of systemic ALCL cases in vivo by immunohistology. Interestingly, 10/12 ALKpositive cases and 5/9 ALK-negative ALCL cases showed cytoplasmic RIP1 expression ( Figure 5c ). As our in vitro data uncovered that RIP1 expression represents the prerequisite for CD30-induced cell death to occur in NFkB-inhibited ALCL cells, the detection of RIP1-positivity might be of This cell death is abolished by RIP1 inhibition, mediated by RIP1 siRNA or Nec-1, for which reason it might be denoted necroptosis. In addition, CD30-induced cell death is also inhibited by the pan-caspase inhibitor z-VAD-fmk, and therefore should be named apoptosis. Our results demonstrate the crucial role of RIP1 in the context of CD30-induced cell death. The model does not cover the entire functional spectrum of RIP1, which is beyond the scope of this work.
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importance for therapeutic approaches of ALCL patients. Combined CD30-stimulation/NFkB-inhibition therapy 29 might only be effective in RIP1 expressing tumor cells. In order to verify the potential correlation of RIP1 and ALK expression, we analyzed gene expression array data of 50 ALCL patient samples that have been obtained from three publicly available data bases (GSE6338, GSE14879, and GSE19069). [24] [25] [26] As depicted in the combined box/dot-plots (Figure 5d ), the entire set of 50 samples is clearly split into two groups, based on ALK (probe set 208212_s_at) expres- 
DISCUSSION
This is the first report that establishes a link between the death domain (DD)-containing serine/threonine kinase RIP1 and the signaling of CD30, a TNFR without DD. DDs are cytoplasmic stretches of TNFRs like TNFR1, TRAILR, and CD95/Fas that mediate death signals. 30 We show that RIP1 is crucially involved in CD30-induced cell death, which can be specifically inhibited by RIP1 siRNA or pharmacologically by the allosteric RIP1 kinase inhibitor Nec-1. 17 In addition to the specific approaches of RIP1 inhibition, we corroborated our findings by the application of GA. GA induces RIP1 degradation by disrupting the function of the RIP1-associating chaperone heat shock protein 90 (Hsp90) but GA is also known to inhibit various proto-oncogenic protein kinases. 31 Here, we demonstrated GA-mediated RIP1 inhibition and abrogation of CD30-induced cell death.
As inhibition of RIP1 kinase activity by Nec-1 efficiently blocked necroptosis 17 , our data clearly indicate that CD30-mediated cell death carries features of necroptosis. 32 Paradoxically, we further revealed that CD30-induced cell death comes along with increased PARP cleavage and caspase-8 activation that can be inhibited by the pancaspase inhibitor z-VAD-fmk. These results demonstrate that caspase-mediated apoptotic mechanisms also have a role in CD30-mediated cell killing. Therefore, CD30-induced cell death cannot be classified according to Galluzzi et al 32 as features of apoptosis and necroptosis appear to be collaborative active under these conditions. Our findings extend current knowledge and match very nicely with recently published work by Knox et al, 8 who demonstrated that RIP1 links the immunoregulatory receptor CD40 to apoptotic signaling in carcinomas. Thus, it becomes apparent that not only DD-containing TNFRs but also TRAF domain-carrying TNFRs like CD30 and CD40 use RIP1 for signal transduction.
Originally, RIP1 was considered to constitute an absolute requirement for TNF-mediated NFkB activation. 33 This view is challenged by recent data where cells from RIP1 À / À knockout mice activated NFkB in response to TNF. 34 These data are in line with our observations. We successfully inhibited RIP1 by siRNA in native ALCL cells, but CD30-mediated NFkB activation, as revealed by NFkB target gene analysis, was not abrogated. Our results clearly indicate that RIP1 is not required for CD30-mediated NFkB activation but instead transmits the CD30 signal to cell death under NFkBinhibited condition. We revealed CD30-mediated canonical and non-canonical NFkB activation in ALCL cell lines, which is in line with previous publications. 4, 35 In addition, we demonstrated CD30-induced non-canonical NFkB activation and CD30-induced Bcl-3 expression to occur in both, native Karpas 299 and NFkB-inhibited DN-Karpas 299 cells. Of note, both, constitutive as well as CD30-induced Bcl-3 expression appears to be lower in constitutively NFkBinhibited DN-Karpas 299 cells as compared with native Karpas 299 cells.
Activation of TNFR1 leads to highly complex polyubiquitination of RIP1 by the ubiquitin ligases cIAP1/cIAP2 and TRAF2. The mode of ubiquitination determines whether RIP1 works as a prosurvival scaffold molecule leading to NFkB activation or as a kinase that mediates cell death. 19, [36] [37] [38] In addition to CD30-regulated NFkB targets, we further analyzed the expression of the TNFR adapter TRAF2 in the context of CD30 signaling. TRAF2 recruits cIAPs to many of the TNFRs, including CD40 39 and CD30 28 and it is degraded during CD30 signaling. 28 We revealed that CD30-induced TRAF2 degradation is more pronounced in DN-Karpas 299 cells as compared with native Karpas 299 cells, pointing out to the importance of NFkB-driven effects on TRAF2-regulation.
As cIAP2 is induced by CD30 stimulation 22, 27 and represents a RIP1 ubiquitin ligase, 18 we analyzed its expression in CD30-stimulated and unstimulated Karpas 299 and DN-Karpas 299 cells. We revealed that NFkBinhibited ALCL cells constitutively express cIAP2 on a very low level and CD30 stimulation is unable to increase cIAP2 protein expression in these cells. Inhibition of cIAPs by BV6, a small molecule that mimics the antagonistic activity of the second mitochondria-derived activator of caspases (Smac), induced auto-ubiquitination and degradation of cIAPs within minutes. 40 Inhibition of cIAP1 and cIAP2 sensitized [24] [25] [26] These publicly available Affymetrix HG-U133 Plus 2.0 array GEO-data (GSE6338, GSE14879, and GSE19069) have been analyzed by Partek Genomic Suite Software. ALCL cases can be subdivided into two significantly different groups, based on ALK expression (P ¼ 9.56e-11) (left panel). RIPK1 expression is not significantly different in ALK-negative and ALK-positive samples (P ¼ 0.507) (right panel).
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B Hirsch et al cells to TNF by the formation of a RIP1-dependent caspase-8-activating complex and culminated in cell death. 9 Therefore, cIAPs and RIP1 represent an 'intimate couple' with deep impact on TNFR-signaling events. 41 In terms of DD-TNFRs like TNFR1, low IAP expression rendered cells sensitive to TNF-induced cell death. 18 Despite the fact that CD30 does not belong to this group of TNFRs, we reasoned whether low cIAP2 expression as measured in DN-Karpas 299 cells is involved in the switching the CD30 signal to cell death. Of note, neither CD30 nor TNF stimulation of native Karpas 299 leads to apoptosis when cells are grown in complete medium with normal serum concentrations. Here, we successfully inhibited IAP expression of Karpas 299 cells by BV6 but neither CD30 nor TNF stimulation induced cell death in these cells. We further revealed that BV6 treatment slightly increased cell death and constitutive expression of the bona fide NFkB target A20/TNFAIP3. Of note, IAP inhibition did not abolish CD30-induced upregulation of A20. However, our data did not disclose a key role for cIAP2 in the context of CD30-induced cell death. Our findings meet published data demonstrating CD30-induced cell death in vitro and in a human Hodgkin lymphoma xenograft model by Bortezomib-mediated proteasome inhibition. 5 Bortezomib is a potent and reversible proteasome inhibitor with clinical efficacy 29 that leads to blockage of IkBa degradation/NFkB activation. Therefore, both aspects of our in vitro model, ie, NFkB inhibition and CD30 stimulation of CD30-positive tumor cells, are applicable to the in vivo situation. However, only patients with RIP1 expression might benefit from bortezomib-mediated NFkB inhibition paralleled by CD30 stimulation. It is, therefore, conceivable to determine RIP1 expression of ALCL tumor samples by immunohistology in order to identify RIP1-positive patients that should be eligible for combined CD30-antibody/NFkB-targeted therapy. 42, 43 To test a possible correlation of RIP1 and ALK expression we analyzed previously published ALCL gene-expression array data sets that covered 50 ALCL cases, where 26/24 cases have been defined to be ALK-positive/-negative, respectively. [24] [25] [26] Based on our analysis of these 50 ALCL samples we conclude that ALK-and RIP1-expression do not correlate (P ¼ 0.507). Therefore, we cannot convey an impact of RIP1 expression on the prognosis of ALK-positive or ALK-negative ALCL.
In vivo, CD30 stimulation is mediated by the interaction of CD30-positive and CD30L-positive cells. 43 Here, we established and functionally validated a cell-based strategy of CD30 stimulation that most closely mimics the physiological situation. Different cell-based CD30L-expressing systems have been applied in the past, first by Smith et al 44 and Csomos, 28 using CV1/EBNA cells and CHO cells, respectively. We established a HeLa-based CD30L expression system to additionally investigate CD30-mediated changes of subcellular protein distribution by confocal laser scanning microscopy. This led us to demonstrate (i) a CD30-induced shift of RIP1 to the cytoplasma membrane and (ii) the RIP1/CD30 co-localization in CD30-stimulated NFkBinhibited ALCL cells. These CD30-induced intracellular changes remind of 'capping' 45 or uropod-like structures that are formed following cytokine-mediated stimulation of T-lymphocytes where flotillin proteins constitute microdomains in the plasma membrane. 46 In conclusion, we identified RIP1 as a new and critical regulator of CD30 signaling. Moreover, RIP1 is important for CD30-induced cell death in NFkB-deficient CD30-positive cells. Interestingly, this RIP1-mediated cell death carries features of both, apoptosis and necroptosis. This notion is very important for therapeutic considerations, as CD30-induced cell death can only be evoked in RIP1 expressing cells in conjunction with NFkB inhibition.
